# US 2012/0269810 A1 · Methods and compositions for panic disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0269810 A1
- Document ID: US20120269810A1
- Status: Published application
- Kind: A1
- Application number: 13/503,609
- Filed: 2010-10-21
- Published: 2012-10-25
- Earliest claimed: 2009-10-24
- Assignees: Indiana University Research and Technology Corporation
- Inventors: Anantha Shekhar; Philip L. Johnson
- Web page: https://patentgrep.com/patent/US20120269810A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 31/438: The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/22: Anxiolytics
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2320/30: Special therapeutic applications
- G01N 2800/301: Anxiety or phobic disorders
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods and compositions that down regulate the activity of orexins to treat panic disorder and panic-like responses associated with hypercapnic conditions are disclosed.

## Claims

### Claim 1

A method of reducing one or more symptoms associated with panic disorder in an individual, the method comprising administering to the individual suffering from panic disorder a composition comprising a therapeutically effective amount of an agent to down regulate the activity an orexin, selected from Orexin A or Orexin B, at one or more orexin receptors.

### Claim 2

A method of treating symptoms associated with hypercapnia or a hypercapnic condition in an individual, the method comprising administering to the individual a composition comprising a therapeutically effective amount of an agent to down regulate the activity of an orexin, selected from Orexin A or Orexin B, at one or more orexin receptors.

### Claim at position 3

-4. (canceled)

### Claim 5 (depends on 2)

The method of claim 2 wherein orexin receptor activity is down regulated at an orexin 1 receptor.

### Claim 6 (depends on 2)

The method of claim 2 wherein orexin receptor activity is down regulated at an orexin 2 receptor.

### Claim 7 (depends on 2)

The method of claim 2 wherein the orexin receptor activity is down regulated at both orexin 1 and orexin 2 receptors.

### Claim 8 (depends on 2)

The method of claim 2 wherein expression of prepro-orexin is decreased.

### Claim 9 (depends on 8)

The method of claim 8 wherein the expression is decreased by a siRNA.

### Claim 10 (depends on 2)

The method of claim 2 wherein expression of an orexin receptor is decreased.

### Claim 11 (depends on 10)

The method of claim 10 wherein the expression is decreased by a siRNA.

### Claim 12 (depends on 2)

The method of claim 2 wherein the agent comprises an orexin receptor antagonist selected from the group consisting of
an orexin receptor antagonist selective for orexin 1 receptors;
an orexin receptor antagonist selective for orexin 2 receptors; and
an orexin receptor antagonist having affinity at orexin 1 receptors and orexin 2 receptors.

### Claim at position 12

-16. (canceled)

### Claim 17 (depends on 12)

The method of claim 12 wherein the orexin receptor antagonist is selected from SB334867, SB408124, MK4305, and almorexant.

### Claim 18 (depends on 2)

The method of claim 2 wherein the agent comprises an antagonistic antibody.

### Claim 19 (depends on 18)

The method of claim 18 wherein the antibody is a single chain antibody fragment.

### Claim 20 (depends on 2)

The method of claim 2 wherein the hypercapnic condition is selected from chronic pulmonary disease, chronic obstructive pulmonary disease (COPD), obstructive sleep apnea syndrome (OSAS), congestive heart failure, sarcoidosis, and/or Pickwick's syndrome.

### Claim 21 (depends on 2)

The method of claim 2 wherein hypercapnia symptom is selected from hypertension, anxiety, elevated sympathetic nervous system activity, elevated respiration, and combinations thereof.

### Claim at position 18

22-23. (canceled)

### Claim 24

A method of determining whether an individual is responsive to a treatment for panic disorder or a hypercapnic associated disorder, the method comprising
determining the levels of orexin in a biological sample from the individual obtained prior to said treatment;
administering said treatment;
determining the levels of orexin in a biological sample from the individual during or after said treatment period,
comparing the levels of orexin present in the sample obtained after initiating treatment to baseline levels of orexin present in the sample obtained prior to treatment, and
determining that the individual is responsive to treatment if orexin levels are reduced during or after said treatment period.

### Claim 25 (depends on 24)

The method of claim 24 wherein the biological sample is cerebrospinal fluid.

### Claim 26

(canceled)
